Vittorio Maglione

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5701174/publications.pdf

Version: 2024-02-01

58 papers	2,446 citations	201674 27 h-index	206112 48 g-index
59 all docs	59 docs citations	59 times ranked	3477 citing authors

#	Article	IF	Citations
1	A Rationale for Hypoxic and Chemical Conditioning in Huntingtonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 582.	4.1	21
2	Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage. International Journal of Molecular Sciences, 2021, 22, 3796.	4.1	8
3	Inhibition of Ceramide Synthesis Reduces Î±-Synuclein Proteinopathy in a Cellular Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6469.	4.1	17
4	Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntingtonâ€™s Disease Model Mice. Brain Sciences, 2021, 11, 1267.	2.3	0
5	An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation. Cell Death and Disease, 2021, 12, 919.	6.3	20
6	Mutant huntingtin interacts with the sterol regulatory element-binding proteins and impairs their nuclear import. Human Molecular Genetics, 2020, 29, 418-431.	2.9	13
7	The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatumâ€“microglia crosstalk preventing disease progression in a mouse model of Huntingtonâ€™s disease. Cell Death and Disease, 2020, 11, 546.	6.3	15
8	Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington's disease. Neurobiology of Disease, 2020, 143, 105009.	4.4	9
9	Curcumin-Loaded Nanoparticles Based on Amphiphilic Hyaluronan-Conjugate Explored as Targeting Delivery System for Neurodegenerative Disorders. International Journal of Molecular Sciences, 2020, 21, 8846.	4.1	15
10	Mitochondrial Respiration Changes in R6/2 Huntingtonâ€™s Disease Model Mice during Aging in a Brain Region Specific Manner. International Journal of Molecular Sciences, 2020, 21, 5412.	4.1	12
11	Curcumin C3 complexÂ®/BioperineÂ® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis. Journal of Experimental and Clinical Cancer Research, 2019, 38, 360.	8.6	19
12	Acute manganese treatment restores defective autophagic cargo loading in Huntingtonâ€™s disease cell lines. Human Molecular Genetics, 2019, 28, 3825-3841.	2.9	18
13	Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntingtonâ€™s disease.. Human Molecular Genetics, 2019, 28, 4012-4021.	2.9	23
14	Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntingtonâ€™s Disease Pre-clinical Model. Frontiers in Molecular Neuroscience, 2019, 12, 100.	2.9	28
15	Glycosphingolipid metabolic reprogramming drives neural differentiation. EMBO Journal, 2018, 37, .	7.8	56
16	Stimulation of S1PR5 with A-971432, a selective agonist, preserves bloodâ€“brain barrier integrity and exerts therapeutic effect in an animal model of Huntingtonâ€™s disease. Human Molecular Genetics, 2018, 27, 2490-2501.	2.9	38
17	The S1P Axis: New Exciting Route for Treating Huntingtonâ€™s Disease. Trends in Pharmacological Sciences, 2018, 39, 468-480.	8.7	29
18	New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases. Current Drug Metabolism, 2018, 19, 478-489.	1.2	26

#	Article	IF	Citations
19	Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. Frontiers in Neuroscience, 2018, 12, 249.	2.8	66
20	Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease. Scientific Reports, 2017, 7, 41316.	3.3	62
21	Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1596-1604.	3.8	29
22	Motor phenotype is not associated with vascular dysfunction in symptomatic Huntingtonâ€™s disease transgenic R6/2 (160 CAG) mice. Scientific Reports, 2017, 7, 42797.	3.3	4
23	Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease. Journal of Visualized Experiments, 2017, , .	0.3	9
24	Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 5280.	3.3	60
25	De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease. Frontiers in Neuroscience, 2017, 11, 698.	2.8	43
26	Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease. Neural Regeneration Research, 2017, 12, 1439.	3.0	2
27	Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models. Frontiers in Neuroscience, 2016, 10, 457.	2.8	24
28	Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease. CNS Neuroscience and Therapeutics, 2016, 22, 686-690.	3.9	19
29	Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Journal of Cellular and Molecular Medicine, 2015, 19, 2540-2548.	3.6	62
30	The Corticospinal Tract in Huntington's Disease. Cerebral Cortex, 2015, 25, 2670-2682.	2.9	33
31	Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease. PLoS ONE, 2014, 9, e89745.	2.5	19
32	MRI measures of corpus callosum iron and myelin in early Huntington's disease. Human Brain Mapping, 2014, 35, 3143-3151.	3.6	42
33	FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Human Molecular Genetics, 2014, 23, 2251-2265.	2.9	84
34	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	4.1	74
35	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. PLoS ONE, 2013, 8, e68951.	2.5	49
36	Changes of peripheral TGF-Î²1 depend on monocytes-derived macrophages in Huntington disease. Molecular Brain, 2013, 6, 55.	2.6	26

#	Article	IF	Citations
37	Tractography of the Corpus Callosum in Huntingtonâ€™s Disease. PLoS ONE, 2013, 8, e73280.	2.5	56
38	Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3528-3533.	7.1	140
39	Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. Journal of Neural Transmission, 2011, 118, 1599-1607.	2.8	15
40	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
41	Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1. Journal of Neuroscience, 2010, 30, 4072-4080.	3.6	117
42	DNA instability in replicating Huntington's disease lymphoblasts. BMC Medical Genetics, 2009, 10, 11.	2.1	24
43	ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. Neuroscience, 2008, 155, 345-349.	2.3	30
44	Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 691-695.	1.7	32
45	The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neuroscience Letters, 2006, 393, 27-30.	2.1	35
46	Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. Journal of Neurochemistry, 2006, 98, 1090-1099.	3.9	31
47	Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mechanisms of Ageing and Development, 2006, 127, 217-220.	4.6	85
48	Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mechanisms of Ageing and Development, 2006, 127, 213-216.	4.6	35
49	Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Human Mutation, 2006, 27, 118-118.	2.5	98
50	New Huntington disease mutation arising from a paternal CAG34allele showing somatic length variation in serially passaged lymphoblasts. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 127-130.	1.7	9
51	Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 101-105.	1.7	31
52	The gender effect in juvenile Huntington disease patients of Italian origin. American Journal of Medical Genetics Part A, 2004, 125B, 92-98.	2.4	41
53	Italian Huntington disease patients-data and tissue bank. Neurological Sciences, 2003, 24, 215-216.	1.9	5
54	Highly disabling cerebellar presentation in Huntington disease. European Journal of Neurology, 2003, 10, 443-444.	3.3	19

#	Article	IF	Citations
55	Mutations in a Gene Encoding a Novel Protein Containing a Phosphotyrosine-Binding Domain Cause Type 2 Cerebral Cavernous Malformations. American Journal of Human Genetics, 2003, 73, 1459-1464.	6.2	319
56	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 2003, 126, 946-955.	7.6	173
57	Onset and pre-onset studies to define the Huntingtonâ€™s disease natural history. Brain Research Bulletin, 2001, 56, 233-238.	3.0	43
58	Cavernous angiomas of the nervous system in Italy: clinical and genetic study. Neurological Sciences, 2000, 21, 129-134.	1.9	11